Literature DB >> 24135006

The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.

Eunju Shin1, Carlo Lisci2, Elisabetta Tronci2, Camino Fidalgo2, Roberto Stancampiano2, Anders Björklund1, Manolo Carta3.   

Abstract

Graft-induced dyskinesia (GID) is a serious complication induced by dopamine (DA) cell transplantation in parkinsonian patients. We have recently shown that DA D2 receptor blockade produces striking blockade of dyskinesia induced by amphetamine in grafted 6-OHDA-lesioned rats, a model of GID. This study was designed to investigate whether blockade of DA D1 receptors could produce similar outcome, and to see whether the effect of these treatments in grafted rats was specific for dyskinesia induced by amphetamine, or could also influence L-DOPA-induced dyskinesia (LID). L-DOPA-primed rats received transplants of fetal DA neurons into the DA-denervated striatum. Beginning at 20weeks after transplantation rats were subjected to pharmacological treatments with either L-DOPA (6mg/kg) or amphetamine (1.5mg/kg) alone, or in combination with the D1 receptor antagonist SCH23390, the D2 receptor antagonist eticlopride, and the 5-HT1A agonist/D2 receptor antagonist buspirone. Grafted rats developed severe GID, while LID was reduced. Both eticlopride and SCH23390 produced near-complete suppression of GID already at very low doses (0.015 and 0.1mg/kg, respectively). Buspirone induced similar suppression at a dose as low as 0.3mg/kg, which is far lower than the dose known to affect LID in non-grafted dyskinetic rats. In agreement with our previous results, the effect of buspirone was independent from 5-HT1A receptor activation, as it was not counteracted by the selective 5-HT1A antagonist WAY100635, but likely due to D2 receptor blockade. Most interestingly, the same doses of eticlopride, SCH23390 and buspirone were found to suppress LID in grafted but not in control dyskinetic rats. Taken together, these data demonstrate that the DA cell grafts strikingly exacerbate the effect of DA D1 and D2 receptor blockade against both GID and LID, and suggest that the anti-GID effect of buspirone seen in patients may also be due to blockade of DA D2 receptors.
© 2013.

Entities:  

Keywords:  Buspirone; Cell transplantation; Dopamine D(1) receptor; Dopamine D(2) receptor; Eticlopride; Graft-induced dyskinesia; L-DOPA-induced dyskinesia; Parkinson's disease; SCH23390

Mesh:

Substances:

Year:  2013        PMID: 24135006     DOI: 10.1016/j.nbd.2013.09.021

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  7 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  Effects of Rho Kinase Inhibitors on Grafts of Dopaminergic Cell Precursors in a Rat Model of Parkinson's Disease.

Authors:  Jannette Rodriguez-Pallares; Ana I Rodriguez-Perez; Ana Muñoz; Juan A Parga; Juan J Toledo-Aral; Jose L Labandeira-Garcia
Journal:  Stem Cells Transl Med       Date:  2016-04-13       Impact factor: 6.940

3.  The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease.

Authors:  Luis F Razgado-Hernandez; Armando J Espadas-Alvarez; Patricia Reyna-Velazquez; Arturo Sierra-Sanchez; Veronica Anaya-Martinez; Ismael Jimenez-Estrada; Michael J Bannon; Daniel Martinez-Fong; Jorge Aceves-Ruiz
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

4.  The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.

Authors:  Natosha M Mercado; Jennifer A Stancati; Caryl E Sortwell; Rebecca L Mueller; Samuel A Boezwinkle; Megan F Duffy; D Luke Fischer; Ivette M Sandoval; Fredric P Manfredsson; Timothy J Collier; Kathy Steece-Collier
Journal:  Neurobiol Dis       Date:  2020-11-11       Impact factor: 5.996

5.  Defining the unknowns for cell therapies in Parkinson's disease.

Authors:  Emma L Lane; Mariah J Lelos
Journal:  Dis Model Mech       Date:  2022-09-27       Impact factor: 5.732

Review 6.  Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia.

Authors:  Elisabetta Tronci; Camino Fidalgo; Manolo Carta
Journal:  Parkinsons Dis       Date:  2015-12-31

7.  6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.

Authors:  Sergio Vegas-Suárez; Clarissa Anna Pisanò; Catalina Requejo; Harkaitz Bengoetxea; Jose Vicente Lafuente; Michele Morari; Cristina Miguelez; Luisa Ugedo
Journal:  Br J Pharmacol       Date:  2020-07-06       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.